Skip to search formSkip to main contentSkip to account menu

linsitinib

Known as: Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, cis-, cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol 
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyOSI 906Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Critical role of SOX2–IGF2 signaling in aggressiveness of bladder cancer
Signaling elicited by the stem cell factors SOX2, OCT4, KLF4, and MYC not only mediates reprogramming of differentiated cells to… 
2017
2017
Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor‐κB signaling in esophageal squamous cell carcinoma
The aim of this study is to evaluate the efficacy of insulin‐like growth factor 1 receptor (IGF‐1R) inhibitor Linsitinib, in… 
2016
2016
Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
Review
2014
Review
2014
International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).
4507 Background: ACC is an uncommon but frequently fatal cancer. For pts with metastatic or recurrent nonoperable ACC, there are… 
2014
2014
99 Combination screening of investigational oncology agents
2013
2013
Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC…
e13502 Background: Linsitinib (OSI-906) is an oral inhibitor of IGF-1R and IR. Increased IGF-1R and IR activity is observed in… 
2013
2013
A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
197 Background: Novel agents capable of blocking AR ligand independent pathways responsible for the development of CRPC are… 
2013
2013
Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib).
e16022 Background: AR ligand independent pathways are responsible for the development of CRPC. IGF-1R and its ligands (IGF-1/IGF… 
Highly Cited
1990
Highly Cited
1990
Methane monooxygenase catalyzed oxygenation of 1,1-dimethylcyclopropane. Evidence for radical and carbocationic intermediates.
Methane monooxygenase catalyzes the oxygenation of 1,1-dimethylcyclopropane in the presence of O2 and NADH to (1… 
1964
1964
A Cyclobutane possessing Hypotensive Activity
A NUMBER of non-quaternary bases have been found to possess ganglionic blocking and hypotensive properties1–5. In investigating… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)